Future Market Insights (FMI) has unveiled a groundbreaking forecast for the global cell and gene therapy manufacturing market, predicting extraordinary growth over the next decade. The latest report forecasts a Compound Annual Growth Rate (CAGR) of 29% from 2023 to 2033, underscoring the market’s rapid expansion and its pivotal role in transforming the healthcare industry.
In 2023, the market achieved an estimated value of USD 19.3 billion, with projections suggesting an exponential rise to approximately USD 240 billion by 2033. This surge follows a strong CAGR of 22% recorded between 2018 and 2022, indicating sustained momentum in the development and production of these life-changing therapies.
One of the reportβs key highlights is the growth of the cell therapy manufacturing sector, which is expected to emerge as the highest revenue-generating segment. The sector is projected to achieve a staggering CAGR of 31.8% from 2023 to 2033, driven by the increasing prevalence of critical diseases such as cancer, along with significant investments in research and development by pharmaceutical companies.
Sabyasachi Ghosh, Associate Vice President at FMI, commented on the findings, stating “The impressive growth projections for the cell and gene therapy manufacturing industry highlight the transformative impact of advanced medical technologies. Our dedication to pioneering innovations and maintaining leadership in this dynamic sector positions us to both contribute to and benefit from this unprecedented growth.”
The report also emphasizes the role of advanced manufacturing technologies in meeting the growing demand for cell and gene therapies across a wide range of diseases. The industry is witnessing a surge in investment, particularly in immunotherapy, gene transfer, and oncolytic virotherapy, all of which play a crucial role in cancer treatment. With over 50 million people expected to be diagnosed with cancer in the next five years, the reliance on gene therapy is projected to intensify, further driving market expansion.
As the global cell and gene therapy manufacturing market continues to evolve, it opens up significant opportunities for collaboration, innovation, and the development of therapies that have the potential to change lives. This positive outlook signals a new era of growth and advancement in medical technology, positioning the industry for sustained success over the next decade.
Report Highlights:
Breast cancer has significantly suppressed lung cancer, by being one of the most commonly diagnosed cancers worldwide. For the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.
Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.
GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.
Cell and Gene Therapy Manufacturing in Demand: Check Out Our Full Report for a Complete Overview of the Trends and Insights!
Competitive Landscape:
The surging interest of key public and private investors in the development of advanced therapies are expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.
Key Companies Profiled:
- Thermo Fisher Scientific
- Merck KGaA
- Lonza
- Catalent Inc.
- Takara Bio Inc.
- F. Hoffmann-La Roche Ltd
- Wuxi Advanced Therapies
- Samsung Biologics
- Boehringer Ingelheim
- Novartis AG
- Hitachi Chemical Co., Ltd.
- Cellular Therapeutics
- Miltenyi Biotec
- Bluebird Bio Inc.
Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis:
By Therapy Type:
- Cell Therapy Manufacturing
- Stem Cell Therapy
- Non-Stem Cell Therapy
- Gene Therapy Manufacturing
By Scale:
- Pre-commercial/ R&D Manufacturing
- Commercial Scale Manufacturing
By Mode:
- Contract Manufacturing
- In-house Manufacturing
By Workflow:
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical And Quality Testing
- Raw Material Testing
- Vector Production
- Other Workflows
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
ππ±π©π₯π¨π«π π ππβπ¬ πππ₯ππππ ππ§π π¨π’π§π ππ¨π―ππ«ππ π π¨π§ ππππ₯ππ‘πππ«π πππ«π€ππ ππ§π¬π’π π‘ππ¬ ππ¨π¦ππ’π§:
Ultrasound Biometry Devices Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:Β Β Β Β Β Β Β Β
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries:Β sales@futuremarketinsights.com
Website:Β https://www.futuremarketinsights.com
LinkedIn|Β Twitter|Β Blogs | YouTube